<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818805</url>
  </required_header>
  <id_info>
    <org_study_id>AL-292ET</org_study_id>
    <nct_id>NCT00818805</nct_id>
  </id_info>
  <brief_title>Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal
      allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in &quot;Ocular Itching&quot; Score (5-point Scale) in Subjective Symptom Questionnaire</measure>
    <time_frame>0-180 minutes after entering the examination room</time_frame>
    <description>Ocular itching score was assessed using a 5 point scale, with 1 meaning no itching and 4 meaning worst itching.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Score in Ocular Symptom Questionnaire</measure>
    <time_frame>15-180 min.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Olopatadine 0.1% one eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranilast 0.5% one eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Olopatadine)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Tranilast)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine 0.1%</intervention_name>
    <description>one drop in one eye</description>
    <arm_group_label>Olopatadine 0.1% one eye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranilast 0.5%</intervention_name>
    <description>one drop in one eye</description>
    <arm_group_label>Tranilast 0.5% one eye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Olopatadine)</intervention_name>
    <description>one drop in contralateral eye</description>
    <arm_group_label>Placebo (Olopatadine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Tranilast)</intervention_name>
    <description>one drop in contralateral eye</description>
    <arm_group_label>Placebo (Tranilast)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age/Gender: males and females aged &gt;20 to &lt; 65 years (at the time of obtaining
             consent).

          2. Positive cases in whom blood specific IgE antibody quantification against cedar pollen
             showed class 2-6 in a health checkup conducted within the past 3 years.

          3. Cases who were diagnosed as patients with seasonal allergic conjunctivitis and were
             judged eligible as subjects of the said study by the investigator or co-investigator
             from the results of medical examination conducted on the day of the study or prior to
             it.

          4. Cases who gave consent on study participation of their own free will in writing, with
             understanding the contents of the said study.

        Exclusion Criteria:

          1. Cases with an ocular disease that requires treatment other than allergic
             conjunctivitis.

          2. Cases with an inflammatory ocular disease in the external/anterior part of the eye
             that may affect drug efficacy evaluation.

          3. Cases with a respiratory disease such as bronchial asthma other than allergic
             rhinitis.

          4. Cases with past history of anaphylaxis.

          5. Cases with past history of hypersensitivity to olopatadine hydrochloride/tranilast.

          6. Cases undergoing immunotherapy (hyposensitization therapy; modulated therapy).

          7. Patients who are pregnant, lactating women, or may be pregnant, or cases wishing to be
             pregnant during the study period.

          8. Other cases who are judged ineligible for participation in the main study by the
             doctor in charge of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>December 3, 2009</results_first_submitted>
  <results_first_submitted_qc>March 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2010</results_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Tranilast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period: May 21-31, 2008 Location: Samoncho Clinic</recruitment_details>
      <pre_assignment_details>The study was conducted using an Ohio chamber in two parts: 1) a proof-of concept pilot study designed to assess the appropriateness of the OHIO chamber to induce ocular symptoms. 2) a randomized, single-masked, placebo-controlled, cross-over study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olopatadine 0.1% First, Then Tranilast Second</title>
          <description>Patients received Olopatadine 0.1% one eye/ Placebo (Olopatadine) in contralateral eye first, then received Tranilast 0.5% one eye/ Placebo (Tranilast) in contralateral eye next</description>
        </group>
        <group group_id="P2">
          <title>Tranilast 0.5% First, Then Olopatadine Second</title>
          <description>Patients received Tranilast 0.5% one eye/ Placebo (Tranilast) in contralateral eye first, then received Olopatadine 0.1% one eye/ Placebo (Olopatadine) in contralateral eye last.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in “Ocular Itching” Score (5-point Scale) in Subjective Symptom Questionnaire</title>
        <description>Ocular itching score was assessed using a 5 point scale, with 1 meaning no itching and 4 meaning worst itching.</description>
        <time_frame>0-180 minutes after entering the examination room</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olopatadine 0.1% One Eye</title>
            <description>Olopatadine 0.1% in one eye in either the first or second period</description>
          </group>
          <group group_id="O2">
            <title>Tranilast 0.5% One Eye</title>
            <description>Tranilast 0.5% in one eye in either the first or second period</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Olopatadine)</title>
            <description>Placebo (Olopatadine) in one eye in either the first or second period</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Tranilast)</title>
            <description>Placebo (Tranilast) in one eye in either the first or second period</description>
          </group>
        </group_list>
        <measure>
          <title>Change in “Ocular Itching” Score (5-point Scale) in Subjective Symptom Questionnaire</title>
          <description>Ocular itching score was assessed using a 5 point scale, with 1 meaning no itching and 4 meaning worst itching.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.47"/>
                    <measurement group_id="O2" value="0.11" spread="0.46"/>
                    <measurement group_id="O3" value="0.06" spread="0.33"/>
                    <measurement group_id="O4" value="0.08" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.61"/>
                    <measurement group_id="O2" value="0.25" spread="0.50"/>
                    <measurement group_id="O3" value="0.33" spread="0.53"/>
                    <measurement group_id="O4" value="0.28" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.70"/>
                    <measurement group_id="O2" value="0.36" spread="0.68"/>
                    <measurement group_id="O3" value="0.50" spread="0.65"/>
                    <measurement group_id="O4" value="0.56" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.76"/>
                    <measurement group_id="O2" value="0.50" spread="0.74"/>
                    <measurement group_id="O3" value="0.75" spread="0.69"/>
                    <measurement group_id="O4" value="0.61" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.82"/>
                    <measurement group_id="O2" value="0.67" spread="0.79"/>
                    <measurement group_id="O3" value="0.92" spread="0.81"/>
                    <measurement group_id="O4" value="0.78" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.81"/>
                    <measurement group_id="O2" value="0.86" spread="0.72"/>
                    <measurement group_id="O3" value="0.92" spread="0.69"/>
                    <measurement group_id="O4" value="0.94" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>105 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.58"/>
                    <measurement group_id="O2" value="0.86" spread="0.72"/>
                    <measurement group_id="O3" value="1.03" spread="0.70"/>
                    <measurement group_id="O4" value="0.97" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.65"/>
                    <measurement group_id="O2" value="1.03" spread="0.70"/>
                    <measurement group_id="O3" value="1.19" spread="0.67"/>
                    <measurement group_id="O4" value="1.08" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>135 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.70"/>
                    <measurement group_id="O2" value="1.14" spread="0.72"/>
                    <measurement group_id="O3" value="1.33" spread="0.72"/>
                    <measurement group_id="O4" value="1.19" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.77"/>
                    <measurement group_id="O2" value="1.14" spread="0.76"/>
                    <measurement group_id="O3" value="1.36" spread="0.64"/>
                    <measurement group_id="O4" value="1.25" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>165 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.78"/>
                    <measurement group_id="O2" value="1.14" spread="0.76"/>
                    <measurement group_id="O3" value="1.39" spread="0.64"/>
                    <measurement group_id="O4" value="1.33" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.77"/>
                    <measurement group_id="O2" value="1.39" spread="0.77"/>
                    <measurement group_id="O3" value="1.44" spread="0.69"/>
                    <measurement group_id="O4" value="1.47" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Score in Ocular Symptom Questionnaire</title>
        <time_frame>15-180 min.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olopatadine 0.1% One Eye</title>
          <description>Olopatadine 0.1% in one eye in either the first or second period</description>
        </group>
        <group group_id="E2">
          <title>Tranilast 0.5% One Eye</title>
          <description>Tranilast 0.5% in one eye in either the first or second period</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Olopatadine) One Eye</title>
          <description>Placebo (Olopatadine) in one eye in either the first or second period</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Tranilast) One Eye</title>
          <description>Placebo (Tranilast) in one eye in either the first or second period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Technical problems with measurement leading to unreliable or uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Labs</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

